Stephan Ursprung

ORCID: 0000-0003-2476-178X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Radiomics and Machine Learning in Medical Imaging
  • Renal cell carcinoma treatment
  • Cancer Genomics and Diagnostics
  • MRI in cancer diagnosis
  • Medical Imaging Techniques and Applications
  • Advanced NMR Techniques and Applications
  • Renal and related cancers
  • Advanced MRI Techniques and Applications
  • Ovarian cancer diagnosis and treatment
  • Atomic and Subatomic Physics Research
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Research Studies
  • Advanced X-ray and CT Imaging
  • Neuroblastoma Research and Treatments
  • Endometrial and Cervical Cancer Treatments
  • Artificial Intelligence in Healthcare and Education
  • AI in cancer detection
  • Mathematical Biology Tumor Growth
  • Statistical Methods in Clinical Trials
  • Prostate Cancer Diagnosis and Treatment
  • Cardiac tumors and thrombi
  • Intraperitoneal and Appendiceal Malignancies
  • Sarcoma Diagnosis and Treatment
  • Photoacoustic and Ultrasonic Imaging
  • Advanced Neuroimaging Techniques and Applications

University of Cambridge
2019-2025

Cancer Research UK Cambridge Center
2020-2025

Universitätsklinikum Tübingen
2023-2025

University Children's Hospital Tübingen
2025

Cambridge University Hospitals NHS Foundation Trust
2023-2025

University of Tübingen
2023-2024

Anna Needs Neuroblastoma Answers
2024

Norwegian Womens Public Health Association
2024

Danube Private University
2023

Cancer Research UK
2019-2022

Machine learning methods offer great promise for fast and accurate detection prognostication of COVID-19 from standard-of-care chest radiographs (CXR) computed tomography (CT) images. Many articles have been published in 2020 describing new machine learning-based models both these tasks, but it is unclear which are potential clinical utility. In this systematic review, we search EMBASE via OVID, MEDLINE PubMed, bioRxiv, medRxiv arXiv papers preprints uploaded January 1, to October 3,...

10.1038/s42256-021-00307-0 article EN cc-by Nature Machine Intelligence 2021-03-15

Our purpose is to investigate the feasibility of imaging tumor metabolism in breast cancer patients using 13 C magnetic resonance spectroscopic (MRSI) hyperpolarized label exchange between injected [1- C]pyruvate and endogenous lactate pool. Treatment-naïve were recruited: four triple-negative grade 3 cancers; two invasive ductal carcinomas that estrogen progesterone receptor-positive (ER/PR+) HER2/neu-negative (HER2−), one 2 3; ER/PR+ HER2− lobular carcinoma (ILC). Dynamic MRSI was...

10.1073/pnas.1913841117 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2020-01-21

Abstract Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a combination untargeted and targeted sequencing methods, applied to two independent cohorts patients ( n = 91) with various tumor subtypes, were used determine ctDNA content plasma urine. Results Our data revealed lower levels RCC relative other cancers similar size stage, detection 27.5% from both cohorts. A...

10.1186/s13073-020-00723-8 article EN cc-by Genome Medicine 2020-02-28

Abstract Background Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the vein (RV) and/or inferior vena cava (IVC) has high peri-surgical morbidity/mortality. NAXIVA assessed response of VTT to axitinib, a potent tyrosine kinase inhibitor. Methods was single-arm, multi-centre, Phase 2 study. In total, 20 patients resectable clear RCC and received upto 8 weeks pre-surgical axitinib. The primary endpoint percentage evaluable improvement by Mayo level on...

10.1038/s41416-022-01883-7 article EN cc-by British Journal of Cancer 2022-06-23

Abstract High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC major obstacle to predicting response neoadjuvant chemotherapy (NACT) and understanding critical determinants response. Here we present framework predict the patients NACT integrating baseline clinical, blood-based, radiomic biomarkers extracted from all primary lesions. We use ensemble machine learning model...

10.1038/s41467-023-41820-7 article EN cc-by Nature Communications 2023-10-24

Purpose To compare hyperpolarized carbon 13 (13C) MRI with dynamic contrast material–enhanced (DCE) in the detection of early treatment response breast cancer. Materials and Methods In this institutional review board–approved prospective study, a woman triple-negative cancer (age, 49 years) underwent 13C after injection [1–carbon {13C}]-pyruvate DCE at 3 T baseline one cycle neoadjuvant therapy. The 13C-labeled lactate-to-pyruvate ratio derived from pharmacokinetic parameters transfer...

10.1148/rycan.2020200017 article EN Radiology Imaging Cancer 2020-07-01

Cancer typically exhibits genotypic and phenotypic heterogeneity, which can have prognostic significance influence therapy response. Computed Tomography (CT)-based radiomic approaches calculate quantitative features of tumour heterogeneity at a mesoscopic level, regardless macroscopic areas hypo-dense (i.e., cystic/necrotic), hyper-dense calcified), or intermediately dense soft tissue) portions.

10.1016/j.compbiomed.2020.103751 article EN cc-by Computers in Biology and Medicine 2020-04-10

Purpose To evaluate glioblastoma (GBM) metabolism by using hyperpolarized carbon 13 (13C) MRI to monitor the exchange of 13C label between injected [1-13C]pyruvate and tumor lactate bicarbonate. Materials Methods In this prospective study, seven treatment-naive patients (age [mean ± SD], 60 years 11; five men) with GBM were imaged at 3 T a dual-tuned 13C–hydrogen 1 head coil. Hyperpolarized was injected, signal acquired dynamic spiral sequence. Metabolism assessed within tumor, in...

10.1148/rycan.210076 article EN Radiology Imaging Cancer 2022-07-01

To determine the accuracy of interpretation a non-contrast MRI protocol in characterizing adnexal masses.Two hundred ninety-one patients (350 masses) who underwent gynecological at our institution between 1st January 2008 and 31st December 2018 were reviewed. A random subset (102 with 121 was chosen to evaluate reproducibility repeatability readers' assessments. Readers evaluated scans retrospectively, assigned 5-point score for risk malignancy gave specific diagnosis. The reference standard...

10.1007/s00330-021-07737-9 article EN cc-by European Radiology 2021-03-16

Background Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy score (CRS) omental tumor deposits. The main limitation of CRS that it requires surgical sampling after initial (NACT) treatment. Earlier and non-invasive predictors could improve patient stratification. We developed computed tomography (CT) radiomic measures predict before NACT as a gold standard. Methods Omental CT-based radiomics...

10.3389/fonc.2022.868265 article EN cc-by Frontiers in Oncology 2022-06-16

Abstract Multiparametric MRI is a promising technique for noninvasive structural and functional imaging of the kidneys that gaining increasing importance in clinical research. Still, there are no standardized recommendations analyzing acquired images need to further evaluate accuracy repeatability currently recommended parameters. The aim study was test-retest renal parameters using different image analysis strategies. Ten healthy volunteers were examined twice with multiparametric protocol...

10.1055/a-2480-4885 article EN RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2025-01-10

Abstract Background: New therapies are needed for patients who experience primary or secondary resistance to renal cell cancer (RCC) treatment. Pre-clinical data suggests PARP inhibitors may be effective RCC in combination with VEGF inhibitors. Neoadjuvant clinical trials offer an opportunity understand the mechanisms of new by comparing tumour and blood before after Methods: WIRE is a window opportunity, phase II, multi-centre, multi-arm, non-randomised, neoadjuvant trial platform...

10.1158/1538-7445.am2025-ct175 article EN Cancer Research 2025-04-25

Abstract Purpose To develop a precision tissue sampling technique that uses computed tomography (CT)–based radiomic tumour habitats for ultrasound (US)-guided targeted biopsies can be integrated in the clinical workflow of patients with high-grade serous ovarian cancer (HGSOC). Methods Six suspected HGSOC scheduled US-guided biopsy before starting neoadjuvant chemotherapy were included this prospective study from September 2019 to February 2020. The segmentation was performed manually on...

10.1007/s00330-020-07560-8 article EN cc-by European Radiology 2020-12-14

Abstract Hyperpolarized 13C-MRI is an emerging tool for probing tissue metabolism by measuring 13C-label exchange between intravenously injected hyperpolarized [1–13C]pyruvate and endogenous lactate. Here, we demonstrate that can be used to detect early response neoadjuvant therapy in breast cancer. Seven patients underwent multiparametric 1H-MRI before 7–11 days after commencing treatment. An increase the lactate-to-pyruvate ratio of approximately 20% identified three who, following 5–6...

10.1158/0008-5472.can-21-1499 article EN cc-by Cancer Research 2021-10-08

Background: Early and accurate grading of renal cell carcinoma (RCC) improves patient risk stratification has implications for clinical management mortality. However, current diagnostic approaches using imaging mass biopsy have limited specificity may lead to undergrading. Methods: This study explored the use hyperpolarised [1-13C]pyruvate MRI (HP 13C-MRI) identify most aggressive areas within tumour patients with clear (ccRCC) as a method guide targeting reduce Six ccRCC underwent...

10.3390/cancers17040569 article EN Cancers 2025-02-07

To evaluate the capability of hyperpolarized [1-13C] pyruvate MRI to predict pathologic response neoadjuvant treatment in multi-site abdominopelvic disease high-grade serous ovarian cancer (HGSOC) patients and compare 13C [18F]-FDG PET/CT measurements for detecting early response. We recruited eight with HGSOC this prospective study who underwent before after first cycle chemotherapy (NACT). Imaging parameters were compared clinical histophatologic parameters. demonstrate here that...

10.1186/s13550-025-01219-5 article EN cc-by-nc-nd EJNMMI Research 2025-04-17

Venous tumor thrombus (VTT) is present in 10-15% patients with renal cell carcinoma (RCC), where the primary invades vein and inferior vena cava, increasing morbidity mortality of curative surgery. Neoadjuvant anti-angiogenic therapies have shown potential to reduce VTT length improve nephrectomy success rates. The NAXIVA trial, a phase II study neoadjuvant axitinib 20 RCC VTT, demonstrated that 35% experienced significant downstaging VTT. However, biological mechanisms driving response or...

10.1158/1538-7445.am2025-1103 article EN Cancer Research 2025-04-21

Abstract Venous tumour thrombus (VTT), where the primary invades renal vein and inferior vena cava, affects 10–15% of cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% response rate after 8 weeks axitinib, VEGFR-directed therapy. However, understanding non-response critical better treatment. Here we show that to axitinib in this setting characterised by distinct predictable set features. We...

10.1038/s41467-025-58436-8 article EN cc-by Nature Communications 2025-04-28

Abstract Computed Tomography (CT) is widely used in oncology for morphological evaluation and diagnosis, commonly through visual assessments, often exploiting semi-automatic tools as well. Well-established automatic methods quantitative imaging offer the opportunity to enrich radiologist interpretation with a large number of radiomic features, which need be highly reproducible reliably clinical practice. This study investigates feature reproducibility against noise, varying resolutions...

10.1038/s41598-021-90985-y article EN cc-by Scientific Reports 2021-06-02
Coming Soon ...